Asterand Logo Home Glossary Contact Us Online Ordering




Share Price
News
Financial Reports
Analyst Coverage
General Information
Corporate Governance
Presentations & Webcasts

Latest News: Commencement of Formal Sales Process

Highlights

Asterand Releases Interim Results for Period Ended 30 June 2011

Download the report

Download Asterand's 2010 Annual Report and Accounts




Highlights

  • Revenue of $11.9 million (H1 2010: $8.7 million)

  • An increase of 36%. Includes full six months of revenue associated with BioSeek as compared to 4.5 months in H1 2010.

  • Operating expenses of $6.6 million (H1 2010: $6.0 million)

  • Includes full six months of operating expenditures associated with BioSeek as compared to 4.5 months in H1 2010

  • Loss for the period of $2.3 million (H1 2010: $1.5 million loss)

  • Includes $1.7 million exceptional interest expense relating to the acquisition of BioSeek

  • EBITDA profit of $0.9 million (H1 2010: $1.4 million loss)


  • Basic loss per 5p Ordinary Share of 1.9c (H1 2010: (1.3)c)


  • Gross Margin of 57% (H1 2010: 50%)


  • Cash resources at 30 June 2011 of $4.7 million (31 December 2010: $5.9 million)


  • Awarded key BioMAP® patents by the US Patent and Trademark office, solidifying the Company’s IP position for this important platform


  • Attained ISO 9001:2008 certification for the Company’s tissue and biobanking operations in Detroit


  • Launched isletOrganDOTTM a novel 3D human cell based model for diabetes research


  • Partnered with 5AM Solutions to create next generation virtual biobanking software to expand access to geographically distinct biospecimen resources


  • Volatile trading experienced post period end (excluding BioSeek) has led to a reduced outlook for the year and the Group is consequently looking to raise funds to bolster working capital


© 2011 Asterand plc. All rights reserved Terms of Use  GryDiv   E-Newsletter